RecruitingRecruiting
Non-nutritive Sweeteners in Inflammatory Bowel Disease
NCT07769437 · University Hospitals Cleveland Medical Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
The Effect of Non-Nutritive Food Sweeteners in Inflammatory Bowel Disease
About this study
Participation in this study will last for a minimum of 35 days (Phase I: 14-days; baseline with removal of all NNS (eg saccharin, sucralose, steviosides, aspartame, acesulfame-k, erythritol) from the diet, Phase II: 21-days; sucralose intervention, and will involve one virtual visit (study visit 1) and two in-person study visits (study visit 2 and study visit 3).
Fecal \& urine samples will be collected before/after each phase. Blood will also be collected.
Eligibility criteria
Inclusion Criteria:
* Age range from: 18 to 70 years.
* Male or female.
* Documented diagnosis of Crohns disease. CD outpatients in remission; Harvey Bradshaw- index in remission (\<6 score).
* Capable of providing consent to participate.
* Able to complete daily surveys and take oral nutrition.
* Able to record meal intake.
* Healthy controls with no diagnosis of IBD or Irritable Bowel Syndrome (IBS).
Exclusion Criteria:
* Short bowel syndrome.
* Hospitalized patients.
* Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients.
* Known drug abuse.
* Known parasitic disease of the digestive system.
* Symptomatic intestinal stricture/narrowing.
* Presence of an ostomy.
* Known active malignancy.
* Antibiotic use within last 14 days.
* Well-founded doubt about the patients cooperation.
* Existing pregnancy or lactation.
* History of \<1 natural bowel movements per 3 consecutive days.
* Unable to access to technology that permits the daily completion of study related activities.
* Change in IBD medication within past 4 weeks.
* Body mass Index \<18 kg/m or ≥35 kg/m.
* Documented C.difficile colitis within four weeks of screening.
* Bariatric surgery
* Phenylketonuria
Study design
Enrollment target: 40 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-02-03
Estimated completion: 2026-12
Last updated: 2026-09-25
Interventions
Other: Sucralose (non-nutritive sweetener)
Primary outcomes
- • Change in fecal microbiome measured by metagenome analysis (Baseline, three weeks pre-intervention, and three weeks after intervention)
Sponsor
University Hospitals Cleveland Medical Center · other
With: Crohn's and Colitis Foundation
Contacts & investigators
ContactAbigail Raffner, RD PhD · contact · Abigail.Raffner@uhhospitals.org · 216-327-6003
ContactSargun Singh, M.B.B.S. · contact · sargun.singh@uhhospitals.org · 216-333-6085
InvestigatorFabio Cominelli, MD PhD · principal_investigator, University Hospitals Cleveland Medical Center
InvestigatorAbigail Raffner, RD PhD · principal_investigator, Case Western Reserve University
All locations (3)
UH Minoff Health CenterRecruiting
Chagrin Falls, Ohio, United States
University Hospitals Cleveland Medical CenterRecruiting
Cleveland, Ohio, United States
UH Westlake Health CenterRecruiting
Westlake, Ohio, United States